Art. -Nr.: HY-145935

NT219

1 Cited Publications

Kundenbewertung

Based on 1 publication(s) in Google Scholar

NT219 is a potent and dual inhibitor of insulin receptor substrates 1/2 (IRS1/2) and STAT3. IRS1/2 and STAT3 are major signaling junctions regulated by various oncogenes. NT219 affects IRS1/2 degradation and inhibits STAT3 phosphorylation. NT219 has the potential for the research of cancer diseases.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 98.57%
CAS. Nr.: 1198078-60-2
Formel: C₁₆H₁₄BrNO₅S
Molecular Weight:412.26

Speicherung:

-20°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

NT219 Chemical Structure

CAS. Nr.: 1198078-60-2

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (1)
Lösungsmittel & Löslichkeit
- In Vitro
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Alle STAT Isoform-spezifische Produkte anzeigen :

In Vitro

NT219 (5 μM, 8 or 12 days) suppresses cancer stem cell viability as monotherapy and synergizes with sotorasib to induce disintegration of established mKRAS (G12C) NSCLC spheroids^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:

H358 (NSCLC) cells
Concentration:

5 µM
Incubation Time:

8 or 12 h
Result:

Synergized with sotorasib to suppress established spheroids.
Demonstrated a significant effect on cell viability in monotherapy treatment of established H358 (NSCLC) spheroids harboring G12C KRAS mutation.

In Vivo

NT219 (20 or 60 mg/kg, i.v., twice a week for 24 days) inhibited tumor cell growth and enhanced the anti-cancer effects of Cetuximab (HY-P9905) and Pembrolizumab (HY-P9902) in the SCC-9 cell xenograft model of recurrent and metastatic head and neck squamous cell carcinoma (NOD scid gamma mice)^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 1198078-60-2
Appearance Solid
Molecular Weight 412.26
Formel C₁₆H₁₄BrNO₅S
Color Yellow to brown
SMILES

OC(C=C1CNC(/C=C/C2=C(C(O)=C(C=C2)O)Br)=S)=C(C(O)=C1)O
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

-20°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Publications (1)

All

Sort by:

Journal Impact Factor

Neurotherapeutics

Reticuline modulates astrocyte and microglial responses to enhance prognosis after traumatic brain injury. [Abstract]

2025 Aug 5:e00709. PMID: 40769849

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : ≥ 100 mg/mL (242.57 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.4257 mL

12.1283 mL

24.2565 mL

5 mM

0.4851 mL

2.4257 mL

4.8513 mL

10 mM

0.2426 mL

1.2128 mL

2.4257 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (274 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Alberto Bessudo, et al. A phase 1/2 study with open-label, dose escalation phase followed by single-arm expansion at the maximum tolerated dose to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of NT219 injection alone and in combination with cetuximab in adults with advanced solid tumors and head and neck cancer.

[2]. Reuveni H, et al. NT219, a dual inhibitor of IRS1/2 and STAT3, suppresses cancer stem cell-mediated resistance to KRASG12C and KRASG12D inhibitors in solid tumors[J]. cell, 2024, 3(2): 1.

[3]. Reuveni H, et al. NT219, a novel dual inhibitor of STAT3 and IRS1/2, demonstrates anti-tumor activity with and without cetuximab in pembrolizumab-resistant head and neck cancer PDX models[C]//Cancer Research. 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA: AMER ASSOC CANCER RESEARCH, 2020, 80(16).

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.4257 mL	12.1283 mL	24.2565 mL	60.6413 mL
	5 mM	0.4851 mL	2.4257 mL	4.8513 mL	12.1283 mL
	10 mM	0.2426 mL	1.2128 mL	2.4257 mL	6.0641 mL
	15 mM	0.1617 mL	0.8086 mL	1.6171 mL	4.0428 mL
	20 mM	0.1213 mL	0.6064 mL	1.2128 mL	3.0321 mL
	25 mM	0.0970 mL	0.4851 mL	0.9703 mL	2.4257 mL
	30 mM	0.0809 mL	0.4043 mL	0.8086 mL	2.0214 mL
	40 mM	0.0606 mL	0.3032 mL	0.6064 mL	1.5160 mL
	50 mM	0.0485 mL	0.2426 mL	0.4851 mL	1.2128 mL
	60 mM	0.0404 mL	0.2021 mL	0.4043 mL	1.0107 mL
	80 mM	0.0303 mL	0.1516 mL	0.3032 mL	0.7580 mL
	100 mM	0.0243 mL	0.1213 mL	0.2426 mL	0.6064 mL

Keywords

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

NT219

Immunology/Inflammation Compound Library

JAK/STAT Compound Library

Kinase Inhibitor Library

Protein Tyrosine Kinase Compound Library

Stem Cell Signaling Compound Library

Anti-Cancer Compound Library

Clinical Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Differentiation Inducing Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Obesity Compound Library

Transcription Factor-Targeted Library

Cancer Stem Cells Compound Library

Metabolic Enzyme Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Anti-Hematopathy Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

Anti-Brain Cancer Compound Library

Protein Kinase Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

Publications Citing Use of MedChemExpress (MCE) NT219

Alle STAT Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (1)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

NT219 Related Classifications

HY-145935 Related Classifications